Long-term darolutamide data show sustained efficacy in nmCRPC
The benefit with darolutamide was observed, regardless of whether or not patients had prior local therapy.
Related Articles
Dr. Tosoian on screening approaches and tools for prostate cancer
“I think in terms of the 2 large tool sets we have, biomarker testing through urine or blood tests and imaging. I think both are…
Dr. Matin on a phase 1b study of infigratinib in localized UTUC
“What we find here was that of the patients who had FGFR3 alterations, 67% of them had tumors that responded,” says Surena F. Matin, MD.
Agreement reached to expand distribution of avanafil for ED
Petros also announced that it has received positive feedback from the FDA after the agency’s informal review of Petros’ technology component for self-selection.
FDA accepts IND application for RAG-01 in NMIBC
The clearance of the IND application for RAG-01 will initiate the launch of clinical trials in the US.
Nivolumab plus chemotherapy nears EU approval for urothelial carcinoma
A decision regarding EU marketing authorization is expected by June 2024.
2024 AUA preview: Dr. Wymer on top research in stone disease
Kevin M. Wymer, MD, highlights 11 studies in stone disease being presented at the 2024 American Urological Association Annual Meeting.
siRNA drug therapy shows promise in clear cell renal cell carcinoma
“ARO-HIF2’s ability to target cancer cells, disrupting a key tumor-driving mechanism, illustrates the potential of siRNA technology in oncology,” says James Brugarolas, MD, PhD.
2024 AUA preview: Dr. Elterman on key research in BPH
Dean S. Elterman, MD, MSc, FRCSC, highlights several studies in BPH being presented at the 2024 AUA Annual Meeting.
Dr. Matin discusses early work with FGFR inhibition in localized UTUC
“And [3 out of 5] of those patients who were initially deemed to go on to nephroureterectomy were able to be converted to endoscopic management,”…
FDA approves pivmecillinam tablets for uncomplicated UTIs
The approval is based on 3 clinical trials evaluating the efficacy of different pivmecillinam dosing regimens in comparison with either placebo, another oral antibacterial drug,…